[123] SUSTAINED VIROLOGICAL RESPONSE RATES WITH PEGINTERFERON a-2a (40 kD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN RANDOMISED CONTROLLED CLINICAL TRIALS ARE REPLICATED IN THE CLINICAL PRACTICE SETTING | Publicación